A Phase 2 interventional study of OC-01 0.1% 0.6 mg/ml and OC-01 (varenicline) nasal spray: 0.2 % (1.2 mg/ml) in Dry Eye Disease, sponsored by Oyster Point Pharma, Inc.. Completed at 1 site in Mexico. Open to participants aged 22 Years and older. Per ClinicalTrials.gov, last updated 2022-06-08.
Sponsored by Oyster Point Pharma, Inc. (part of Viatris Inc.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies testing varenicline in Dry Eye Syndromes — 2 open to participants now, 2 under way, none of them phase 3. Varenicline · Dry Eye Syndromes.
Among the 13 studies testing varenicline in Dry Eye Syndromes, this one is the 4th largest by enrollment, is one of 2 that started in 2019, is one of 3 in phase 2, and was the 3rd registered.
1,369 studies on the registry are indexed under Dry Eye Syndromes; 208 are open to participants now.
Browse Dry Eye Syndromes studies →2 of the 13 studies testing varenicline in Dry Eye Syndromes are open now, in 1 country. Recruiting first, the newest first:
Ocular Aesthetics, LLC dba Ocular Clinical Trials · Sites in United States
Ages 18–99 · Healthy volunteers
University of California, Berkeley · Sites in United States
Ages 18+
By country, each count listing its studies:
Varenicline: first FDA approval 2006 (CHANTIX), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →
Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.
This study: 22 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2018; this study’s year is marked. 2 started in 2019.
This study's enrollment of 123 is above the median of 60 across 1,129 interventional studies indexed under Dry Eye Syndromes.
Median enrollment 60 across the 13 interventional studies. Of the 10 that completed or were terminated, 5 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 13 have an industry lead sponsor. The 9 most frequent:
This study is registered under Oyster Point Pharma, Inc., one of the names counted as Viatris Inc.. Under that name alone:
Oyster Point Pharma, Inc. is the lead sponsor of 11 studies on the registry; none are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 10 (100%) have results posted.
Viatris Inc. has 9 studies filed under Dry Eye Syndromes — fewer than ten, so there is no comparison to draw.
2 of the studies testing varenicline in Dry Eye Syndromes that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07705893Ocular Aesthetics, LLC dba Ocular Clinical TrialsTreating Contact Lens Discomfort With Varenicline Solution Nasal Spray 0.03mg | 2026-12 |
| NCT07606625University of California, BerkeleyOcular Surface Health and Tear Film Stability With a Nasal Spray Dry Eye Treatment | 2026-12-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 13 studies testing varenicline in Dry Eye Syndromes, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The objective of this study is to evaluate the chronic safety and effectiveness of OC-01 Nasal Spray as compared to placebo on signs of dry eye disease (DED).
Study OPP-004 was a Phase 2, single-center, randomized, masked (including subjects, Investigators, and study site personnel), placebo-controlled study designed to evaluate the safety and efficacy of OC-01 (varenicline) nasal spray in adult subjects with DED. The study planned to randomize approximately 120 subjects at least 22 years of age with a physicians' diagnosis of Dry Eye Disease and meeting all other study eligibility criteria to receive an application of OC-01 or placebo BID for 12 weeks. Subjects who terminated early during the application period were asked to complete safety assessments (if the subjects agree) prior to study exit. Subjects who were terminated early from the study were not replaced.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
OC-01 (varenicline) nasal spray, 0.6 mg/mL
Drug: OC-01 0.1% 0.6 mg/ml
OC-01 (varenicline) nasal spray, 1.2 mg/mL
Drug: OC-01 (varenicline) nasal spray: 0.2 % (1.2 mg/ml)
vehicle control
Other: placebo comparator
Drug page: Varenicline
OC-01 (varenicline) nasal spray: 0.1 % (0.6 mg/ml)
Also known as: varenicline
Drug page: Varenicline
OC-01 (varenicline) nasal spray: 0.2 % (1.2 mg/ml)
Also known as: varenicline
vehicle control
Mean Change in Schirmer's Test Score From Baseline to 84 Days
The Schirmer's test measures the amount of tears produced by numbing the eye and placing a paper strip in the eye for 5 minutes and distance of wetting was recorded following treatment with OC-01 or placebo. Schirmer's test scores range from 0-35 mm where a higher score is indicative of a better outcome.
Time frame: Visit 1 (baseline) and Visit 6 (84 days)
Percent of Subjects Who Achieve ≥10 mm Improvement in Schirmer's Test Score From Baseline at Visit 6 (Day 84)
The Schirmer's test measures the amount of tears produced by numbing the eye and placing a paper strip in the eye for 5 minutes and distance of wetting was recorded following treatment with OC-01 or placebo. Schirmer's test scores range from 0-35 mm where a higher score is indicative of a better outcome.
Time frame: Visit 1 (baseline) and Visit 6 (84 days)
Percent of Subjects Who Achieve ≥10 mm Improvement in Schirmer's Test Score From Baseline at Visit 4 (Day 28)
The Schirmer's test measures the amount of tears produced by placing a paper strip in the eye for 5 minutes and the distance of wetting was recorded following treatment with OC-01 or placebo. Schirmer's test scores range from 0-35 mm where a higher score is indicative of a better outcome.
Time frame: Visit 1 (baseline) and Visit 4 (28 Days)
Mean Change in Schirmer's Test Score From Baseline to 84 Days (Visit 6) - Fellow Eye
The Schirmer's test measures the amount of tears produced by numbing the eye and placing a paper strip in the eye for 5 minutes and distance of wetting was recorded following treatment with OC-01 or placebo. Schirmer's test scores range from 0-35 mm where a higher score is indicative of a better outcome.
Time frame: Visit 1 (baseline) to Visit 6 (84 Days)
Mean Change in Schirmer's Test Score From Baseline to 28 Days (Visit 4) - Study Eye
The Schirmer's test measures the amount of tears produced by numbing the eye and placing a paper strip in the eye for 5 minutes and distance of wetting was recorded following treatment of OC-01 or placebo. Schirmer's test scores range from 0-35 mm where a higher score is indicative of a better outcome.
Time frame: Visit 1 (baseline) to Visit 4 (28 days)]
Mean Change in Schirmer's Test Score From Baseline to 28 Days (Visit 4) - Fellow Eye
The Schirmer's test measures the amount of tears produced by numbing the eye and placing a paper strip in the eye for 5 minutes and distance of wetting was recorded following treatment with OC-01 or placebo. Schirmer's test scores range from 0-35 mm where a higher score is indicative of a better outcome.
Time frame: Visit 1 (baseline) to Visit 4 (28 Days)
Mean Change in Total Corneal Fluorescein Staining
A standardized grading system of 0-3 is used for each of the five areas of the cornea (inferior, superior, nasal, temporal, central). Grade 0 will be specified when no staining is present. The total score ranges from 0-15. Lower scores indicate improvement.
Time frame: Visit 1 (baseline) and Visit 5 (56 days)
| Milestone | OC-01 0.1%, 0.6 mg/ml | OC-01 0.2%, 1.2 mg/ml | Placebo |
|---|---|---|---|
| Started | 41 | 41 | 41 |
| Completed | 36 | 29 | 32 |
| Not completed | 5 | 12 | 9 |
| Withdrew: Adverse event | 1 | 3 | 3 |
| Withdrew: Lost to follow-up | 4 | 4 | 5 |
| Withdrew: Protocol violation | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 4 | 1 |
The Schirmer's test measures the amount of tears produced by numbing the eye and placing a paper strip in the eye for 5 minutes and distance of wetting was recorded following treatment with OC-01 or placebo. Schirmer's test scores range from 0-35 mm where a higher score is indicative of a better outcome.
| mm | OC-01 0.1%, 0.6 mg/ml | OC-01 0.2%. 1.2 mg/ml | Placebo |
|---|---|---|---|
| Mean Change in Schirmer's Test Score From Baseline to 84 Days | 10.8 ± 1.29 | 11.0 ± 1.29 | 6.0 ± 1.29 |
The Schirmer's test measures the amount of tears produced by numbing the eye and placing a paper strip in the eye for 5 minutes and distance of wetting was recorded following treatment with OC-01 or placebo. Schirmer's test scores range from 0-35 mm where a higher score is indicative of a better outcome.
| Participants | OC-01 0.1%, 0.6 mg/ml | OC-01 0.2%, 1.2 mg/ml | Placebo |
|---|---|---|---|
| Percent of Subjects Who Achieve ≥10 mm Improvement in Schirmer's Test Score From Baseline at Visit 6 (Day 84) | 15 | 20 | 10 |
The Schirmer's test measures the amount of tears produced by placing a paper strip in the eye for 5 minutes and the distance of wetting was recorded following treatment with OC-01 or placebo. Schirmer's test scores range from 0-35 mm where a higher score is indicative of a better outcome.
| Participants | OC-01 0.1%, 0.6 mg/ml | OC-01 0.2%. 1.2 mg/ml | Placebo |
|---|---|---|---|
| Percent of Subjects Who Achieve ≥10 mm Improvement in Schirmer's Test Score From Baseline at Visit 4 (Day 28) | 18 | 17 | 12 |
The Schirmer's test measures the amount of tears produced by numbing the eye and placing a paper strip in the eye for 5 minutes and distance of wetting was recorded following treatment with OC-01 or placebo. Schirmer's test scores range from 0-35 mm where a higher score is indicative of a better outcome.
| mm | OC-01 0.1%, 0.6 mg/ml | OC-01 0.2%. 1.2 mg/ml | Placebo |
|---|---|---|---|
| Mean Change in Schirmer's Test Score From Baseline to 84 Days (Visit 6) - Fellow Eye | 7.9 ± 1.19 | 8.7 ± 1.18 | 4.8 ± 1.18 |
The Schirmer's test measures the amount of tears produced by numbing the eye and placing a paper strip in the eye for 5 minutes and distance of wetting was recorded following treatment of OC-01 or placebo. Schirmer's test scores range from 0-35 mm where a higher score is indicative of a better outcome.
| mm | OC-01 0.1%, 0.6 mg/ml | OC-01 0.2%. 1.2 mg/ml | Placebo |
|---|---|---|---|
| Mean Change in Schirmer's Test Score From Baseline to 28 Days (Visit 4) - Study Eye | 10.2 ± 1.42 | 11.4 ± 1.42 | 6.9 ± 1.42 |
The Schirmer's test measures the amount of tears produced by numbing the eye and placing a paper strip in the eye for 5 minutes and distance of wetting was recorded following treatment with OC-01 or placebo. Schirmer's test scores range from 0-35 mm where a higher score is indicative of a better outcome.
| mm | OC-01 0.1%, 0.6 mg/ml | OC-01 0.2%. 1.2 mg/ml | Placebo |
|---|---|---|---|
| Mean Change in Schirmer's Test Score From Baseline to 28 Days (Visit 4) - Fellow Eye | 5.4 ± 1.36 | 9.2 ± 1.35 | 6.7 ± 1.35 |
A standardized grading system of 0-3 is used for each of the five areas of the cornea (inferior, superior, nasal, temporal, central). Grade 0 will be specified when no staining is present. The total score ranges from 0-15. Lower scores indicate improvement.
| units on a scale | OC-01 0.1%, 0.6 mg/ml | OC-01 0.2%, 1.2 mg/ml | Placebo |
|---|---|---|---|
| Mean Change in Total Corneal Fluorescein Staining | -3.3 ± 0.56 | -3.7 ± 0.6 | -3.2 ± 0.59 |
Collected over Adverse Events were collected from the first dose of study drug administration until the final study visit at Visit 6 (84 days).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| OC-01 0.1%, 0.6 mg/ml | 0/41 (0%) | 0/41 (0%) | 4/41 (9.8%) |
| OC-01 0.2%, 1.2 mg/ml | 0/41 (0%) | 0/41 (0%) | 5/41 (12.2%) |
| Placebo | 0/41 (0%) | 0/41 (0%) | 4/41 (9.8%) |
| Event | OC-01 0.1%, 0.6 mg/ml | OC-01 0.2%, 1.2 mg/ml | Placebo |
|---|---|---|---|
| Ocular TEAEsEye disorders | 4/41 | 5/41 | 4/41 |
| Visual acuity reducedEye disorders | 4/41 | 3/41 | 3/41 |
| SneezingRespiratory, thoracic and mediastinal disorders | 2/41 | 3/41 | 2/41 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 0/41 | 0/41 | 2/41 |
| Throat irritationRespiratory, thoracic and mediastinal disorders | 2/41 | 0/41 | 0/41 |
| HeadacheNervous system disorders | 2/41 | 2/41 | 0/41 |
| NauseaGastrointestinal disorders | 0/41 | 1/41 | 2/41 |
| Conjunctival hyperaemiaEye disorders | 0/41 | 0/41 | 1/41 |
| Eye irritationEye disorders | 0/41 | 1/41 | 0/41 |
| Eyelid oedemaEye disorders | 0/41 | 0/41 | 1/41 |
Subjects in the ITT population
| Age, Continuous(years) | OC-01 0.1%, 0.6 mg/ml | OC-01 0.2%, 1.2 mg/ml | Placebo | Total |
|---|---|---|---|---|
| Mean | 51.4 ± 13.18 | 54.2 ± 11.77 | 55.8 ± 26.77 | 53.8 ± 12.75 |
| Sex: Female, Male(Participants) | OC-01 0.1%, 0.6 mg/ml | OC-01 0.2%, 1.2 mg/ml | Placebo | Total |
|---|---|---|---|---|
| Female | 32 | 35 | 33 | 100 |
| Male | 9 | 6 | 8 | 23 |
| Race/Ethnicity, Customized(Participants) | OC-01 0.1%, 0.6 mg/ml | OC-01 0.2%, 1.2 mg/ml | Placebo | Total |
|---|---|---|---|---|
| Race, Other | 41 | 41 | 41 | 123 |
| Hispanic or Latino | 41 | 41 | 41 | 123 |
| Baseline Schirmer's Test Score(mm) | OC-01 0.1%, 0.6 mg/ml | OC-01 0.2%, 1.2 mg/ml | Placebo | Total |
|---|---|---|---|---|
| Mean | 5.5 ± 2.46 | 5.4 ± 2.47 | 5.3 ± 2.04 | 5.4 ± 2.33 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Feb 2019 to primary completion in Jan 2020, 10 months.
Results were first posted in Jun 2022, 2 years 5 months after primary completion.
Of 75 industry-sponsored phase 2 interventional studies under Dry Eye Syndromes, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 11. This study's 10 months is above that.
Counting every sponsor, half of 91 studies reached it within 7 months; a quarter within 5 and three quarters within 12.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Varenicline